Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 612 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Central Mechanisms That Regulate Glucose Metabolism in Humans

NCT01028846
Conditions
Type 2 Diabetes, Glucose Metabolism Disorders, Glucose, High Blood
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes
Interventions
Boost Glucose Control (A), Boost Glucose Control (B), Boost Original
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
20 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Tustin, California
Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
Empagliflozin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sugar-replacement Sweeteners, and Blood Sugar Control

NCT01128829
Conditions
Obesity
Interventions
Water, Sucralose
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions
Oral Glucose Tolerance Test
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Not listed Not applicable Interventional Accepts healthy volunteers

Role of Sweetness in Glucose Regulation

NCT03844230
Conditions
Obesity
Interventions
Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition, Control- Stimulation, Experimental I- Stimulation, Experimental II- Stimulation, Sensory Evaluation
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Champaign, Illinois
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
143
States / cities
Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ureteral Jets on Cystoscopy

NCT02476448
Conditions
Injury of Ureter
Interventions
Normal saline, Phenazopyridine, Dextrose 10%, Sodium Fluorescein
Drug
Lead sponsor
Cecilia Calvo
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Weston, Florida
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetes Mellitus
Interventions
Alogliptin and metformin, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin 10mg then Placebo Oral Tablet, Placebo Oral Tablet then Dapagliflozin 10mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting No phase listed Observational

Pregnancy and Postpartum CGM in GDM

NCT07174245
Conditions
Gestational Diabetes
Interventions
continuous glucose monitor
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Tadalafil and Glycemic Traits

NCT01444651
Conditions
Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Thomas J. Wang, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 3 Interventional Results available

Prevention of Cystic Fibrosis Diabetes

NCT00967798
Conditions
Cystic Fibrosis, Prediabetes
Interventions
Sitagliptin
Drug
Lead sponsor
Emory University
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Markers of Early Pancreas Cancer

NCT03568630
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Not applicable Interventional Accepts healthy volunteers

Arginine Metabolism in Youth With Type 2 Diabetes

NCT05477134
Conditions
Type 2 Diabetes
Interventions
Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions
Chromium
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Derby, Connecticut
Conditions
Glucose Transporter Type 1 Deficiency Syndrome
Interventions
UX007
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • New York, New York + 2 more